X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

EMBO Molecular Medicine

期刊標題檢索 EMBO MOL MED 最新評論: Hello, I would like to ask if it is necessary to submit all the raw da... (2023-02-03)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[EMBO Molecular Medicine]您好,您是該頁面的第 79435 位訪客。

期刊簡介
期刊名稱EMBO Molecular Medicine EMBO Molecular Medicine
LetPub Score
8.8
50 ratings
Rate

Reputation
9.4

Influence
8.1

Speed
9.7

期刊簡稱EMBO MOL MED
ISSN1757-4676
E-ISSN1757-4684
h-index90
CiteScore
CiteScoreSJRSNIPCiteScore Rank
17.703.9641.787
Subject fieldQuartilesRankPercentile
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Molecular Medicine
Q112 / 178

自引率 (2023-2024)1.10%自引率趨勢
掲載範囲
EMBO Molecular Medicine is an open access journal dedicated to science at the interface between clinical research and the life sciences.

EMBO Molecular Medicine has a fair and transparent process (http://embomolmed.embopress.org/about#Transparent_Process) to rapidly publish important science. Anonymous referee reports and editorial correspondence are published alongside manuscripts as Review Process Files in the Transparent Process section online.
官方網站http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1757-4684
在線稿件提交http://embomolmed.msubmit.net/cgi-bin/main.plex
開放訪問Yes
出版商Wiley-Blackwell
主題領域医学
出版國/地區ENGLAND
發行頻率月刊
創刊年2009
每年文章數112每年文章數趨勢
黃金OA百分比53.50%
OA Related Info
APC: Yes( EUR6490; GBP5590; USD6890; )
APC waiver:Check Notes
Other charges: No
Keywords: molecular medicine、cell biology、translational medicine
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review、Double anonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
MEDICINE, RESEARCH & EXPERIMENTALSCIEQ115/189
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1757-4676%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Sort of slow, 4-8 Week(s)
競爭力 *來自作者的數據: Difficult
參考鏈接
相關期刊 【EMBO Molecular Medicine】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    JOURNAL OF CLINICAL INVESTIGATIONH-index: 447

    CiteScore: 24.50
    JOURNAL OF BIOMEDICAL SCIENCEH-index: 71

    CiteScore: 18.50
    CLINICAL SCIENCEH-index: 126

    CiteScore: 11.40
    Journal of Translational MedicineH-index: 87

    CiteScore: 10.00
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINEH-index: 80

    CiteScore: 12.30
    JOURNAL OF MOLECULAR MEDICINE-JMMH-index: 127

    CiteScore: 9.30
    ARCHIVES OF MEDICAL RESEARCHH-index: 72

    CiteScore: 12.50
    Orphanet Journal of Rare DiseasesH-index: 87

    CiteScore: 6.30
    XENOTRANSPLANTATIONH-index: 56

    CiteScore: 6.80
    CLINICAL AND EXPERIMENTAL MEDICINEH-index: 39

    CiteScore: 4.80
    學科內最受檢索的期刊 頁面查看次數
    Journal of Translational Medicine255687
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE172373
    JOURNAL OF CLINICAL INVESTIGATION168233
    JOURNAL OF BIOMEDICAL SCIENCE131242
    CLINICAL SCIENCE88154
    MEDICAL SCIENCE MONITOR84721
    Advances in Experimental Medicine and Biology81135
    EXPERIMENTAL BIOLOGY AND MEDICINE75990
    JOURNAL OF MOLECULAR MEDICINE-JMM75276
    ARCHIVES OF MEDICAL RESEARCH74190
  •  

    EMBO Molecular Medicine EMBO Molecular Medicine
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [EMBO Molecular Medicine] 的評論撰寫評論
作者: 安娜66


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-03 11:20:40 評論於
Hello, I would like to ask if it is necessary to submit all the raw data when submitting an article to this magazine? Thank you!
(0) 讚! | 安娜66

作者: 辉夜一莹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-06 21:26:36 評論於
Review speed: 2.0 | Submission acceptance rate: 25.0 Experience sharing: EMBO Press, the third sibling of EMBO, focuses mainly on clinical drug development. The number of submissions is not high, but the quality is good. Rejections are also quick. EMBO's journals are actually very good and won't waste your time. The editors are friendly
(0) 讚! | 辉夜一莹

作者: 随意


領域: 生物学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2022-06-08 19:29:09 評論於
Rejected within three days of submission, they said it didn't meet the criteria for their magazine.
(0) 讚! | 随意

作者: 建利少爷


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-01 13:35:50 評論於
Do you need to upload the original data?
(0) 讚! | 建利少爷

作者: 昕靓小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-01 08:51:24 評論於
Can you translate the following paragraph into English and Japanese, respectively, with headers ":" and ":"
(0) 讚! | 昕靓小姐姐

作者: 金蛇海东


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-21 08:18:57 評論於
What is antibody validation data?
(0) 讚! | 金蛇海东

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 23:11:15 評論於
The triple lines include top line, column line, bottom line, and other auxiliary lines can be added. The components of the three-line table include: table number, table title, item column, table body, table note
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 18:03:04 評論於
High resolution images (supporting file formats tiff, bmp, psd, gif, pdf) etc
(0) 讚! | 维尔娜菲茨杰拉德

作者: 修然小公主


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 16:29:07 評論於
What is a three-line table?
(0) 讚! | 修然小公主

作者: Oswald Edie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 23:01:24 評論於
What format do general journals require for graphs and charts?
(0) 讚! | Oswald Edie

作者: 长安余妍


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-06-08 21:38:32 評論於
Is it considered under editorial consideration once submitted?
(0) 讚! | 长安余妍

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-12-31 17:27:04 評論於
The score of EMBO Journal is approximately over 9 points, and the scores of several journals are generally stable. EMBO Molecular Medicine is expected to increase to 10 points in 2020. There were few journals with a score of 10 in the past, so EMBO Journal is relatively influential. However, as there are more and more journals with a score of over 10 now, its reputation is not as strong as before
(0) 讚! | 法慧和同

作者: 重阳文景


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-04-18 21:51:23 評論於
Money is not a problem, as long as it can be issued, the unit's reward is enough to cover the layout fee. Mao Dading 2018-02-26 15:37:00 Published: OPEN ACCESS article, the layout fee is expensive, 3000 euros, various antibodies and so on need to be verified data, it is very cumbersome, in turn can be understood as high data reliability. IF is getting higher every year
(0) 讚! | 重阳文景

作者: dianannan


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2019-03-30 11:20:35 評論於
It was under editorial consideration immediately, and be rejected in 5 days. But the rejection letter is far-fetched. But I can transfer it to other EMBO journals.

(0) 讚! | dianannan

作者: 玉卿姑娘


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-03-29 17:09:14 評論於
Under editorial consideration now, rejected in 5 days. However, the rejection letter seemed forced. But you can consider submitting to another EMBO journal
(0) 讚! | 玉卿姑娘

作者: 折梅丁巳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-02-26 18:50:41 評論於
Review speed: 1.0 | Submission acceptance rate: 50.0
Sharing experience: The article of OPEN ACCESS has a high publication fee of 3000 euros, and various antibodies require validation data, which is quite cumbersome. On the other hand, it can be understood as high data credibility. The impact factor is increasing every year
(0) 讚! | 折梅丁巳

作者: 康平酱大魔王


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-12-06 12:35:40 評論於
How much is the layout fee?
(0) 讚! | 康平酱大魔王

作者: 折梅丁巳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-02-08 21:02:03 評論於
Articles in OPEN ACCESS journals are expensive in terms of publication fees, and validation data is required for various antibodies, making the process quite cumbersome. However, the Impact Factor is indeed increasing
(0) 讚! | 折梅丁巳

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [EMBO Molecular Medicine] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*